- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07441772
TOE Study: Treatment and Gait Analysis fOllowing an Excised Lesser Toe (TOE)
A Feasibility Randomised Controlled Study to Examine the Effect of Otoform Toe Dividers in the Treatment of Patients With Diabetes Mellitus Following a Lesser Toe Amputation
Summary of study
The study will examine patients with Diabetes Mellitus (DM) who have had a lesser toe amputations (LTA) (toes 2nd3rd,4th or 5th). It is currently not understood how this affects the way patients walk and foot function. No previous studies have been undertaken to examine this and its potential for causing further ulceration risk.
This study is a feasibility study. It is designed to see if it is possible to undertake a large, randomised trial. It will explore how participants are recruited, kept in the study and how easy it is to follow the study protocol.
Aim of the study
Establish the feasibility of a corresponding full scale investigation into to the effectiveness of a toe divider made from Otoform for patients with DM following an LTA.
Study Design
- Participants will be recruited from Mid Yorkshire NHS teaching Hospital.
- Participants will be randomised to receive either standard care or an otoform toe divider.
- Participants age, gender, medical history, medication and blood sugar levels will be recorded.
- Vascular and neurological assessments, foot posture and toe deformities will be undertaken and recorded.
- All participants will have pressures measured on the plantar aspects of both feet.
- Follow up visits will be arranged every 6 weeks for12 months for all participants to monitor foot health and changes in walking pattern and pressure redistribution.
- If an ulceration or other foot complication occurs, the participants will be removed from the study and appropriate treatment given (the rescue arm of the study).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is currently being undertaken in part fulfil a PhD and because the research questions have not previously been answered.
The main study questions are:
- Can a large scale randomised control trial been undertaken using the methodology of the feasibility study?
- How does gait and foot function change after an LTA in patients with DM?
- Does an Otoform toe divider improve foot function and affect pressure redistribution reducing the risk of ulcerations?
- Can the research learn how to research, write, execute and evaluate a feasibility study as part of her PhD?
There is no previous research examining the effects that DM and an LTA have on gait and foot structure or the use of toe dividers manufactured from otoform as a treatment following an LTA. It is not known why these patients are at risk of developing further ulcerations and where on the foot these are likely to be. It is known that up to 60% of patients who have DM and an LTA require further surgery including revision surgery, further minor amputations or major amputations. None of the studies that established this did not look at why. This study aims in part to answer this.
This subject area has also been selected as toe dividers are routinely given to patients and there is anecdotal evidence to support this but how effective they have not been studied. It has also been chosen as there are no current guidelines or recommendation on how to treat this patient group. An Otoform toe divider has been selected as it is the most used material from which toe dividers are made. This was established after a questionnaire was sent to health care workers involved in the care of patients with DM and LTA. The questionnaire asked what treatments were used and what materials were chosen and why. This questionnaire has fulfilled the first part of the researchers PhD. Further material testing at the University of Huddersfield's engineering department found that Otoform was more effective in dealing with compression and deformation forces than other materials commonly involved (silicone gel and semi compressed felt). The other two materials were found not to withstand these forces as well as Otoform. Semi compressed felt could also not be washed which created a hygiene issue.
The study has been design to run over a 12 month period as previous studies have suggested that if a participants going to develop an ulceration it will be within the first 12 months after a lesser toe amputation. 12 months has also been selected to examine both the short and long term effects of wearing a toe divider. 6 weeks has been chosen to review participants to examine any changes in foot health. The methodology has been reviewed at each stage with the researcher by her supervision team which is comprised of researchers, clinicians and a statistician. The methodology has also been discussed with patients and clinicians.
The results from the initial visit will be compared with the literature to establish how participants in this study compare to participants in other studies that examined gait in those without DM, in DM without neuropathy and DM with neuropathy but without any amputations. It has been chosen to do this as several studies have already been undertaken to examine the gait patterns in these patient groups. It would be unethical to ask participants to take part in a study when this information is already available.
Patients, their careers and the public have been involved in the development of the study through speaking to patients and through the James Lund Alliance. The James Lund Alliance is a not-for-profit organisation, established in 2006 to look at health priorities, medical uncertainties and unanswered medical questions (James Lund, 2024a). Priorities are set by bringing together patients, carers, and clinicians (James Lund, 2024a). Under the priority "vascular conditions", one area pertinent to this study is the Diabetic Foot (James Lund, 2024b). The questions under "Diabetic Foot" relevant to this study are:
2) What are effective methods of preventing further amputations following a toe amputation? 7) What is the most effective way to prevent DFUs returning? (James Lund Alliance, 2021a).
The study has been discussed and read by patients who attend a diabetes centre who have had a LTA. The discussion bought to attention that participants may not be able to afford to attend the clinics so home visits or reimbursement for parking charges may be required.
Only participants with capacity will be included in the study. The researcher undertaking the study has had the necessary training to assess if an individual has the capacity to provide informed consent to take part in the study. Where English is not the participants first language, an interpreting service is available to allow the participant to understand the study and provide the necessary consent.
It is appreciated that participants may not be able to commit for a 12 month period but as no previous studies have been undertaken it is not known if this is possible. As the study is a feasibility study the boundaries of the study are being explore and if drop out is too high then the protocol may need to be adjusted to reflect this. It is also appreciated that there is a potential risk of an ulcer forming as the toe divider may rub. To reduce this risk the toe dividers are custom made to each individual participant and they will be monitored every 6 weeks.
As the researcher is also a clinician there is the potential that she may know some of the participants recruited for the study. The conflict of interest will be kept to a minimum by explaining the purpose of the study what treatments will be received and what treatments. This will enable patients expectations to be managed.
There are potential benefits to be gained from taking part in the study. These include improvement in balance, the potential to keep toes in a better position post operatively, a pressure map of the patient's foot which highlights areas that may ulcerate before they do. This currently is not a service that is offered within the trust where the research will take place but has been shown by previous studies to reduce the risk of ulceration.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Abigail R Dagg
- Phone Number: 07904456874
- Email: abigail.dagg@hud.ac.uk
Study Contact Backup
- Name: Abigail R Dagg
- Phone Number: 07904456874
- Email: abigail.dagg@nhs.net
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants over the age of 18.
- Participants with DM and a lesser toe amputation.
- Participants who wish to take part and provide informed written consent
- Participants who are mobile (including those who use walking aids).
Exclusion Criteria
- Participants under the age of 18.
- Participants who do not have DM.
- Participants who have active ulcerations or surgical sites.
- Participants who had had a 1st toe and/or ray amputation.
- Participants with neuroarthropathy or other marked foot deformities.
- Participants who already wear a toe divider.
- Participants who have a known allergy to the silicone or catalyst being used.
- Participants who are immobile.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Study Arm
The study group will be given a toe divider
|
Otoform is a moldable silicone used to make a toe divider.
|
|
No Intervention: Control Arm
Participants will continue to receive regular treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptibility of wearing a toe divider
Time Frame: From enrollment and then every 6 weeks for 52 weeks.
|
theoretical frame work of acceptability questionnaire
|
From enrollment and then every 6 weeks for 52 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak Pressure
Time Frame: From enrollment and then every 6 weeks for 52 weeks.
|
Peak pressure and where the points of peak pressure are located.
|
From enrollment and then every 6 weeks for 52 weeks.
|
|
Pressure time integral
Time Frame: From enrollment and then every 6 weeks for 52 weeks.
|
Time spent on a certain point of the foot and for how long
|
From enrollment and then every 6 weeks for 52 weeks.
|
|
Contact Area
Time Frame: From enrollment and then every 6 weeks for 52 weeks.
|
Area of the foot that is in contact with the ground
|
From enrollment and then every 6 weeks for 52 weeks.
|
|
Foot Posture Index
Time Frame: From enrollment and then every 6 weeks for 52 weeks.
|
The foot posture index will be used to measure foot posture
|
From enrollment and then every 6 weeks for 52 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: John Stephenson, Huddersfield University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SREIC/2024/047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
State University of New York at BuffaloMedical University of South Carolina; National Institute of Diabetes and Digestive...CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Leiden University Medical CenterAndaluz Health ServiceCompletedDiabetes Mellitus | Health Behavior | Self Efficacy | Type2 Diabetes Mellitus | Type1 Diabetes MellitusNetherlands, Spain
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
Clinical Trials on Otoform toe divider
-
Medical University of GdanskMinistry of Science and Higher Education, PolandUnknown
-
Albert Einstein Healthcare NetworkCompletedStroke | HemiparesisUnited States
-
Istanbul Training and Research HospitalCompleted
-
Medical University of ViennaCompletedHemorrhage | Otorhinolaryngologic Diseases | Postoperative Pain | Surgery--Complications | Postoperative Hemorrhage | Tonsillectomy | Tonsillitis Chronic | HandlingAustria
-
Centre Assal for Foot Medicine and Surgery SARecruitingHallux ValgusSwitzerland
-
Mahidol UniversityUnknown
-
Bahar AnaforogluNot yet recruitingHallux Valgus Deformity
-
Riphah International UniversityNot yet recruiting
-
Riphah International UniversityCompletedSports Physical TherapyPakistan